Showing 1261-1270 of 1371 results for "".
- James P. Hartman Tapped as New Vice President and General Manager at Solta Medicalhttps://modernaesthetics.com/news/james-p-hartman-tapped-as-new-vice-president-and-general-manager-at-solta-medical/2472174/James P. Hartman is the new Vice President and general manager at Solta Medical, a division of Valeant Pharmaceuticals North America LLC. Mr. Hartman joined Solta Medical from Merz Aesthetics (a division of
- New from Silk'n: Meet Titan by Silk'nhttps://modernaesthetics.com/news/new-from-silkn-meet-titan-by-silkn/2472181/Home-use devices represent a hot growth category, and Silk'n is now introducing Titan by Silk'n for at-home skin tightening and lifting. Titan combines infrared energy to increase blood circulation and improve skin tone and texture, LED lig
- FDA Clears Fotona's StarWalker MaQX Ultra Performance Q-Switched Systemhttps://modernaesthetics.com/news/fda-clears-fotonas-starwalker-maqx-ultra-performance-q-switched-system/2472191/The FDA has cleared Fotona's StarWalker MaQX Q-Switched laser system for treating tattoos, pigmented and vascular lesions, acne and scar revision, and permanent hair reduction. The Verde 532 mode in a "tattoo laser" is exclusive to the MaQX. Sales in the US will begin immediately. T
- Bonti's Gateway Neuromodulator Performs Well in Phase 2A Studyhttps://modernaesthetics.com/news/bontis-gateway-neuromodulator-performs-well-in-pase-2a-for-glabellar-lines/2472208/Bonti’s lead product candidate, EB- 001, passed muster in a Phase 2A study for the treatment of glabellar lines. EB-001 is a novel serot
- Syneron Candela Becomes Private Company with Completion of Transaction with Funds Advised by Apax Partnershttps://modernaesthetics.com/news/syneron-candela-becomes-private-company-with-completion-of-transaction-with-funds-advised-by-apax-partners/2472211/Syneron Medical Ltd. announced the successful completion of its acquisition by an affiliate of funds advised by Apax Partners for $11.00 per share in cash in a transaction valued at approximately $400 million. The transacti
- Allergan CEO Calls for Consensus on Medical Aesthetic Treatment in Minorshttps://modernaesthetics.com/news/allergan-ceo-calls-for-consensus-on-medical-aesthetic-treatment-in-minors/2472213/Allergan Chairman & CEO Brent Saunders, the father of two high school-aged girls, is speaking up and out about the risks associated with offering medical aesthetic treatments to minors. In a new blog post, he writes “we must remember that anyone under the age of 18 is still matu
- There's a New Pico in Town: Wontech's Picocare Scores FDA Nodhttps://modernaesthetics.com/news/theres-a-new-pico-in-town-wontechs-picocare-scores-fda-nod/2472218/The U.S. Food and Drug Administration (FDA) cleared WONTECH’s picosecond laser device for tattoo removal. PICOCARE removes tattoos in various colors in less time with 1064nm, 532nm, 595nm, and 660nm wavelengths and selectively removes pigment par
- New AAFPRS Data: More Than 30 Percent of Men Are Considering Nips and Tuckshttps://modernaesthetics.com/news/new-aafprs-data-more-than-30-percent-of-men-are-considering-nips-and-tucks/2472223/The plastic surgery ‘menaissaince’ may really be a thing, finds a new survey from the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS). It turns out that 31 percent of men said they are “extremely likely&rdq
- ThermiGen, an Almirall company, Names Vladimir Paul-Blanc President & General Managerhttps://modernaesthetics.com/news/thermigen-an-almirall-company-names-vladimir-paul-blanc-president-general-manager/2472245/Vladimir Paul-Blanc has been named President & General Manager of ThermiGen, LLC, starting May 1. He will report directly to the Executive Vice-president of Commercial Strategy of Almirall, Alfonso Ugarte, and he will be responsible for all general management responsibilities for the Thermi b
- Survey: Many Bothered By Double Chins, Take Steps To Cover Uphttps://modernaesthetics.com/news/survey-many-bothered-by-double-chins-take-steps-to-cover-up/2472259/Close to 50 percent of individuals are bothered by the appearance of the area under their chin, and many alter their behavior as a result, according to a new survey commissioned by Allergan plc.<